Tenon Medical Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted an expanded indication for the use of their Catamaran® SI Joint Fusion System. This approval allows the system to be used to augment immobilization and stabilization of the sacroiliac (SI) joint for patients undergoing sacropelvic fixation as part of a lumbar fusion. The company believes this regulatory milestone will open a substantial new market opportunity by addressing the need for robust SI joint stabilization in complex spinal fusion procedures. This expanded indication aims to enhance patient care for those suffering from SI joint disorders by providing a dependable and efficient method for authentic SI joint fusion.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。